- Credit Type: CPE
- Credit Amount: 1.00
- Cost: $5.00
- Release: Feb 9, 2015
- Expires: Oct 23, 2017
- Estimated Time to Complete:
- System Requirements:
Average User Rating:
Anticoagulation Program Coordinator
UK HealthCare Pharmacy Services
Associate Adjunct Professor, Pharmacy Practice and Science
University of Kentucky College of Pharmacy
Needs StatementNeed: Novel oral anticoagulants are increasing in use and pharmacists need to be aware of efficacy and safety issues.
Gap: In the past, oral anticoagulation therapy had limited options (e.g., warfarin) but novel oral anticoagulants provide an alternative therapy and require additional education to use in current practice.
ObjectivesUpon Completion of this activity Pharmacist will be able to:
1. Summarize the pharmacology and indications for the novel oral anticoagulants
2. Illustrate how pharmacists can impact the safe and efficacious use of the novel oral anticoagulants
The University of Kentucky College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This application-based activity has been assigned UAN 0022-0000-15-012-H01-P and will award 1.00 contact hour (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.Statements of participation will indicate hours and CEUs based on participation and will be issued online at the conclusion of the activity. Successful completion includes completing the activity, its accompanying evaluation and/or posttest (score 70% or higher) and requesting credit online at the conclusion of the activity. Credit will be uploaded to CPE Monitor, and participants may print a statement of credit or transcript from their NABP e-profile. The College complies with the Accreditation Standards for Continuing Pharmacy Education.
Faculty DisclosureGeorge A. Davis, PharmD (Speaker) has no relevant financial relationships with commercial interests.
George Davis does not intend to discuss the off-label use of a product.
No planners have any relevant financial relationships to disclose.
Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.